Debra M Foster

Ms. Debra M Foster


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 June 2014 in Trials
Verified
Journal Article
Open access
PDF file
DKDavid J Klein
David J Klein
DFDebra M Foster
Debra M Foster
CSChrista A Schorr
Christa A Schorr
KKKazem Kazempour
Kazem Kazempour
PWPaul M Walker
Paul M Walker
RDR Phillip Dellinger
R Phillip Dellinger
Septic shock is common and has unacceptably high morbidity, mortality, and associated cost with numerous failed attempts at developing effective therapies. Endotoxin, one of the most potent mediators of sepsis, is found in high levels in approximately 50% of patients with septic shock. Polymyxin B (PMX) hemoperfusion has been shown in numerous studies to successfully remove endotoxin and potentially improve outcomes. EUPHRATES (Evaluating the Use of Polymyxin B Hemoperfusion in a Randomized controlled trial of Adults Treated for Endotoxemia and Septic shock) is a theragnostic trial (matching blood measurement to treatment capability) of PMX hemoperfusion in patients with septic shock and confirmed endotoxemia as measured by the endotoxin activity assay (EAA).

Verified
Journal Article
Open access
PDF file
DFDebra M Foster
Debra M Foster
JKJohn A Kellum
John A Kellum
Endotoxin, also referred to as lipopolysaccharide (LPS), is a potent stimulator of the inflammatory cascade which may progress to sepsis and septic shock. The term endotoxic septic shock has been used for patients who have a clinical phenotype that is characterized by high endotoxin activity in addition to a high burden of organ failure; especially a pattern of organ failure including hepatic dysfunction, acute kidney injury, and various forms of endothelial dysfunction. Endotoxic septic shock has been a target for drug therapy for decades with no success. A likely barrier to their success was the inability to quantify endotoxin in the bloodstream. The Endotoxin Activity Assay (EAA) is positioned to change this landscape. In addition, medical devices using adsorptive technology in an extra-corporeal circulation has been shown to remove large quantities of endotoxin from the bloodstream. Focusing on the use of EAA to determine high concentrations of endotoxin will allow patients with endotoxic septic shock to be identified quickly and these patients may benefit most from removal of endotoxin using extracorporeal methods.

16 March 2026 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
RCRishi Chanderraj
Rishi Chanderraj
BBBrian Bartek
Brian Bartek
KSKathleen Stringer
Kathleen Stringer
MTMohamad H. Tiba
Mohamad H. Tiba
MSMichael W. Sjoding
Michael W. Sjoding
PSPratik Sinha
Pratik Sinha
BACKGROUND: Sepsis encompasses considerable biological and clinical heterogeneity. Previously, 2 phenotypes (“hyperinflammatory” and “hypoinflammatory”) have been consistently identified within sepsis via latent class analysis. These phenotypes differ in their biological features, clinical outcomes, and therapeutic responses to interventions. Prior studies of sepsis heterogeneity have focused primarily on the host response. Here, we investigate the potential influence of the causative pathogen on sepsis heterogeneity and pathobiology. METHODS: We performed a retrospective observational analysis of 8,280 critically ill patients with sepsis to identify associations between pathogen characteristics and the hyperinflammatory and hypoinflammatory patient phenotypes. We also performed controlled murine and swine modeling of sepsis and lung injury and a secondary analysis of 449 patients enrolled in the EUPHRATES randomized controlled trial. RESULTS: Pathogen characteristics (pathogen identity, burden, virulence, and anatomic site of infection) were strongly and independently associated with the previously reported phenotypes. In a cohort of critically ill patients with sepsis, infection with gram-negative pathogens, primarily Enterobacterales spp. (e.g., Escherichia coli , Klebsiella pneumoniae ), was strongly associated with the hyperinflammatory phenotype. The hyperinflammatory phenotype was also independently associated with increased pathogen burden, virulence, and initial anatomic site of infection. In controlled murine and swine modeling, both the identity and burden of the pathogen provoked key biological features of the hyperinflammatory phenotype. Among patients with sepsis, the prognostic value of lactate clearance varied substantially by phenotype. In a secondary analysis of a randomized trial of polymyxin B hemoadsorption (which removes circulating endotoxin), hypoinflammatory patients experienced worse survival. CONCLUSIONS: Our results demonstrate the central importance of pathogen features in the clinical and biological heterogeneity of sepsis. Future studies of sepsis pathobiology and heterogeneity should expand their scope beyond the host response, as understanding pathogen-host interactions will be crucial in the development of precision therapeutic strategies to improve patient outcomes. TRIAL REGISTRATION: EUPHRATES trial NCT01046669. FUNDING: 5P30AG024824, IK2CX002766, R01HL144599, K24HL159247, R01HL158626, R01HL173531, R35GM142992, R35GM145330, R35GM136312, K23HL166880, R35HL140026.

28 August 2025 in Critical Care Explorations
Verified
Journal Article
Open access
LMLuca Molinari
Luca Molinari
MTMark A. Tidswell
Mark A. Tidswell
AAAli Al-Khafaji
Ali Al-Khafaji
DDDanielle Davison
Danielle Davison
CGClaude Galphin
Claude Galphin
JKJohn A Kellum
John A Kellum
IMPORTANCE: The relationship between endotoxin activity, organ failure, and mortality is not well understood. OBJECTIVE: To test whether the combination of endotoxin activity and organ failure identifies patients at higher risk of death from sepsis and determine the relationship to previously described sepsis phenotypes. DESIGN, SETTING, AND PARTICIPANTS: Prospective observational study in four ICUs enrolling critically ill patients with septic shock. MAIN OUTCOMES AND MEASURES: Endotoxin activity assay (EAA) results, Sequential Organ Failure Assessment (SOFA), and multiple organ dysfunction (MODS) and 28-day mortality. RESULTS: We enrolled 90 patients aged 25–95 years and set an EAA cutoff of greater than or equal to 0.6 together with SOFA greater than 11 or MODS greater than 9 to define endotoxic septic shock (ESS). At baseline mean EAA was 0.64 (sd = 0.19), whereas mean SOFA and MODS were 10.3 (sd 3.2) and 5.8 (sd 3.1), respectively. EAA greater than or equal to 0.6 and SOFA greater than 11 were present in 20 patients (23.3%) and these patients had 60% mortality. EAA greater than or equal to 0.6 and SOFA less than or equal to 11 occurred in 31 (36.0%) with mortality 12.9%. Of the 35 remaining patients with EAA less than 0.6, 29 (33.7%) had SOFA less than or equal to 11 and 5 of them (17.2%) died. Only six patients (7.0%) had EAA less than 0.6 and SOFA greater than 11 and none died (p < 0.001). All patients with MODS greater than 9 also had EAA greater than or equal to 0.6 (12 patients) with 75% mortality. EAA greater than or equal to 0.6 with MODS less than or equal to 9 occurred in 39 patients with 17.9% mortality (p < 0.001). ESS (EAA ≥ 0.6 together with SOFA > 11 or MODS > 9) occurred in 21 patients and they had significantly higher mortality (57.1% vs. 15.9%, p < 0.001) compared with non-ESS, with a relative risk for death of 3.58 (95% CI, 1.86–6.91). Among ESS patients, 7 (33.3%) had δ phenotype, whereas only 4 (5.8%) had δ among non-ESS (p = 0.001). CONCLUSIONS AND RELEVANCE: ESS compromises patients with the highest mortality rate from sepsis. Such patients are most appropriate for trials testing anti-endotoxin therapy for improving survival.

5 August 2025 in Critical Care Explorations
Verified
Journal Article
Open access
MMMichael McCurdy
Michael McCurdy
Timothy SweeneyTimothy Sweeney
Timothy Sweeney
DFDebra M Foster
Debra M Foster
BRBobby Reddy
Bobby Reddy
SSSteven Q. Simpson
Steven Q. Simpson
FPfor Sepsis Alliance and the Infection Management and Sepsis Collaborative Community (IMSCC) Panelists
for Sepsis Alliance and the Infection Management and Sepsis Collaborative Community (IMSCC) Panelists
OBJECTIVES: To characterize regulatory and clinical adoption challenges to developing host-based sepsis diagnostics and to establish a common framework for stakeholders to work together toward potential solutions to these challenges. DESIGN: Expert review, structured interviews, and small group discussions with experienced clinicians and experts in diagnostic test development and regulatory issues. SETTING: A series of large and small group conference calls conducted from January 2023 to September 2024, along with a review of the available evidence and scope of the issue. SUBJECTS: A collaborative group of multinational and multidisciplinary sepsis-focused patient advocacy groups, academic research groups, regulatory experts, and executives and clinical leaders from private companies assembled by Sepsis Alliance’s Infection Management and Sepsis Collaborative Community. INTERVENTIONS: The implications of existing regulatory practices surrounding the evaluation of host-based sepsis diagnostics were examined using structured, small group interviews and discussions. The entire expert panel collated the findings of small groups, and consensus was achieved on the most salient points. MEASUREMENTS AND MAIN RESULTS: For various reasons, current regulatory practices surrounding host-based sepsis diagnostics pose significant challenges to both regulators and product developers in creating optimal clinical tools. The most important barriers to regulatory approval were considered to be: classification of the diagnostic tests’ goals and output, heterogeneity of sepsis presentation and course, and lack of universal definitions of sepsis. Potential solutions to the challenges were informally proposed, but were not explored rigorously at this project phase. CONCLUSIONS: A collaborative statement was created outlining the challenges of developing diagnostic tests and devices for sepsis, including existing regulatory requirements surrounding host-based sepsis diagnostics and their implications for ultimate clinical deployment. Characterizing these challenges is a necessary first step to establish a common framework for stakeholders to effectively engage in discussions to develop potential solutions.

18 November 2009 in Journal of Organ Dysfunction
Verified
Journal Article
Closed access
IHIbtesam Hilmi
Ibtesam Hilmi
JKJohn A Kellum
John A Kellum
RPRaymond Planinsic
Raymond Planinsic
DFDebra M Foster
Debra M Foster
AAAli Abdullah
Ali Abdullah
KAKareem Abu-Elmagd
Kareem Abu-Elmagd
Objective. Patients undergoing orthotopic liver transplantation (OLT) and multi-visceral transplantation (MVT) may have an increased incidence of endotoxemia due to translocation of endotoxin from the intestine, in combination with impaired hepatic clearance. We sought to evaluate the presence of endotoxemia in the perioperative period, using the Endotoxin Activity Assay™ (EAA) to understand the association of endotoxin activity (EA) with clinical course and outcome. Material and methods. In this prospective observational pilot study we measured EA in 40 patients undergoing OLT or MVT during the perioperative period. As a control, the EAA was performed on 10 healthy adult volunteers. We analyzed the relationships between EA and graft function, episodes of rejection, infection and outcome. Results. Mean EA in the control group was 0.21±0.05 u (range 0.16–0.27 u). For patients, baseline pre-transplant EA was significantly greater than that in controls at 0.50±0.17 u (range 0.10–0.80 u) (p=0.001) and further increased post-reperfusion (p=0.018) during OLT, especially in patients who developed post-reperfusion syndrome (PRS) (p=0.029). In the postoperative phase, EA remained elevated (>0.40 u) in nearly 75% of patients for up to 1 month post-surgery but was greatest (>0.60 u) for patients who developed infection. However, postoperative EA did not correlate with length of hospital or intensive care unit stay or with 90-day survival. Conclusions. High EA is common before, during and after abdominal organ transplantation and is associated with PRS, infection and rejection. However, unlike other critically ill patients, high EA in this cohort does not necessarily affect short-term prognosis. Further study will delineate the utility of measuring EA in the abdominal transplant population.